# A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

> **NCT00923247** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 22 (actual)

## Conditions studied

- Medullary Thyroid Carcinoma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Vandetanib

## Key facts

- **NCT ID:** NCT00923247
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-02-19
- **Primary completion:** 2016-04-01
- **Final completion:** 2016-12-09
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Terminated due to slow accrual,primary endpoint reached \& investigator left NIH.
- **Last updated:** 2018-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00923247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00923247, "A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00923247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*